Chroma Medicine Stock
HealthTechLooking to sell Chroma Medicine stock or options?
Chroma Medicine is advancing genomic medicines aimed at transforming the treatment of genetically influenced diseases. The company's innovative approach leverages epigenetics, the natural mechanism for regulating genes, by employing programmable epigenetic editors. These editors specifically target genes and manage chromatin structure by pairing a DNA binding domain with epigenetic effector domains. This enables healthcare professionals to utilize a new class of therapeutics, achieving unprecedented precision in controlling gene expression.
DCVC Bio, Wellington Management, ARCH Venture Partners, Cormorant Asset Management, Atlas Venture, Sofinnova Partners, GV, Casdin Capital, Janus Capital Management, Janus Henderson Investors, Newpath Partners, Sixth Street Partners, Alexandria Real Estate Equities, Osage University Partners, Mubadala Capital, T. Rowe Price Group, Omega Funds.
Collective explained in 2 minutes
Learn how Collective's solutions enable you to manage your risk and maximize your wealth
Our available services for this company
Management Team
Board Members
Chroma Medicine’s stock FAQs
Chroma Medicine is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Chroma Medicine stock. Depending on Chroma Medicine’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Chroma Medicine stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Chroma Medicine stock in two ways. First, Chroma Medicine employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Chroma Medicine stock. Note that all transactions in Chroma Medicine shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Chroma Medicine stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Chroma Medicine stock. Typically, shares of private companies like Chroma Medicine are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Mar 2023, Chroma Medicine is reported to have closed an equity financing in which the investors valued the company at $451M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Chroma Medicine shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Chroma Medicine is not currently publicly traded, it does not have a ticker symbol.
Chroma Medicine has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Chroma Medicine is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Chroma Medicine shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
